Neutrophil migration and production of reactive oxygen species during treatment with a fully human anti-tumor necrosis factor-α monoclonal antibody in patients with rheumatoid arthritis

Journal of Rheumatology

Volumn 30, Issue 2, 2003, Pages 232-237

  Den Broeder, Alfons A ^a   Wanten, Geert J A ^a   Oyen, Wim J G ^a   Naber, Ton ^a   Van Riel, Piet L C M ^a   Barrera, Pilar ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adalimumab; Anti tumor necrosis factor ; Neutrophil migration; PMN; Reactive oxygen species; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; CYTOCHROME C; LUMINOL; MONOCLONAL ANTIBODY; PHORBOL 13 ACETATE 12 MYRISTATE; REACTIVE OXYGEN METABOLITE; STREPTOZOCIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; ZYMOSAN;

ADULT; AGED; ARTICLE; CELL MIGRATION; CHEMOLUMINESCENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; ENZYME ASSAY; FEMALE; HUMAN; HUMAN CELL; MALE; NEUTROPHIL CHEMOTAXIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REDUCTION; RHEUMATOID ARTHRITIS; SCINTIGRAPHY;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; CELL MOVEMENT; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUTROPHILS; REACTIVE OXYGEN SPECIES; RESPIRATORY BURST; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037309513     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
2. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
3. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
4. Liu Z, Simpson RJ, Cheers C. Interaction of interleukin-6, tumour necrosis factor and interleukin-1 during Listeria infection. Immunology 1995;85:562-7.
5. Nakane A, Okamoto M, Asano M, Kohanawa M, Minagawa T. Endogenous gamma interferon, tumor necrosis factor, and interleukin-6 in Staphylococcus aureus infection in mice. Infect Immun 1995;63:1165-72.
6. Mastroeni P, Villarreal Ramos B, Hormaeche CE. Effect of late administration of anti-TNF alpha antibodies on a Salmonella infection in the mouse model. Microb Pathog 1993;14:473-80.
7. Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 2001;344:1099-100.
8. Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol 2001;96:722-9.
9. Schuurman B, Heuff G, Beelen RH, Meyer S. Enhanced killing capacity of human Kupffer cells after activation with human granulocyte/macrophage-colony-stimulating factor and interferon gamma. Cancer Immunol Immunother 1994;39:179-84.
10. Han SK, Brody SL, Crystal RG. Suppression of in vivo tumorigenicity of human lung cancer cells by retrovirus-mediated transfer of the human tumor necrosis factor-alpha cDNA. Am J Respir Cell Mol Biol 1994;11:270-8.
11. Keller R, Keist R, Wechsler A, Leist TP, van der Meide PH. Mechanisms of macrophage-mediated tumor cell killing: a comparative analysis of the roles of reactive nitrogen intermediates and tumor necrosis factor. Int J Cancer 1990;46:682-6.
12. Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000;43:2383-90.
13. Russell E, Zeihen M, Wergin S, Litton T. Patients receiving etanercept may develop antibodies that interfere with monoclonal antibody laboratory assays. Arthritis Rheum 2000;43:944.
14. Ferrante A. Tumor necrosis factor alpha potentiates neutrophil antimicrobial activity: increased fungicidal activity against Torulopsis glabrata and Candida albicans and associated increases in oxygen radical production and lysosomal enzyme release. Infect Immun 1989;57:2115-22.
15. Ferrante A. Augmentation of the neutrophil response to Naegleria fowleri by tumor necrosis factor alpha. Infect Immun 1989;57:3110-5.
16. Shau H. Characteristics and mechanism of neutrophil-mediated cytostasis induced by tumor necrosis factor. J Immunol 1988;141:234-40.
17. Moore AR, Iwamura H, Larbre JP, Scott DL, Willoughby DA, Cartilage degradation by polymorphonuclear leucocytes: in vitro assessment of the pathogenic mechanisms. Ann Rheum Dis 1993;52:27-31.
18. Kowanko IC, Ferrante A. Adhesion and TNF priming in neutrophil-mediated cartilage damage. Clin Immunol Immunopathol 1996;79:36-42.
19. Kraan MC, de Koster BM, Elferink JG, Post WJ, Breedveld FC, Tak PP. Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis: findings in a prospective, randomized, double-blind clinical trial in fifteen patients. Arthritis Rheum 2000;43:1488-95.
20. Laurindo IM, Mello SB, Cossermelli W. Influence of low doses of methotrexate on superoxide anion production by polymorphonuclear leukocytes from patients with rheumatoid arthritis. J Rheumatol 1995;22:633-8.
21. Mur E, Zabernigg A, Hilbe W, Eisterer W, Halder W, Thaler J. Oxidative burst of neutrophils in patients with rheumatoid arthritis: influence of various cytokines and medication. Clin Exp Rheumatol 1997;15:233-7.
22. Al Balla S, Johnston C, Davis P. The in vivo effect of nonsteroidal anti-inflammatory drugs, gold sodium thiomalate and methotrexate on neutrophil superoxide radical generation. Clin Exp Rheumatol 1990;8:41-5.
23. Youssef PP, Cormack J, Evill CA, et al. Neutrophil trafficking into inflamed joints in patients with rheumatoid arthritis, and the effects of methylprednisolone. Arthritis Rheum 1996;39:216-25.
24. Soykan I, Ertan C, Ozden A. Severe anaphylactic reaction to infliximab: report of a case. Am J Gastroenterol 2000;95:2395-6.
25. Paleolog EM, Hunt M, Elliott MJ, Feldmann M, Maini RN, Woody JN. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis. Arthritis Rheum 1996;39:1082-91.
26. Tak PP, Taylor PC, Breedveld FC, et al. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 1996;39:1077-81.
27. Okuda A, Kubota M, Watanabe K, et al. Inhibition of superoxide production and chemotaxis by methotrexate in neutrophils primed by TNF-alpha or LPS. Eur J Haematol 1997;59:142-7.
28. Salfeld J, Kaymakcalan Z, Tracey D, Roberts A, Kamen R. Generation of fully human anti-TNF antibody D2E7 [abstract]. Arthritis Rheum 1998;41 Suppl:S57.
29. Schattenkirchner M, Kruger K, Sander O, et al. Efficacy and tolerability of weekly subcutaneous injections of the fully human anti TNF antibody D2E7 in patients with rheumatoid arthritis. Results of a phase I study [abstract]. Arthritis Rheum 1998;41 Suppl:S57.
30. Rau R, Sander O, den Broeder A, et al. Long term efficacy and tolerability of multiple i.v. doses of the fully human anti-TNF antibody D2E7 in patients with rheumatoid arthritis. Arthritis Rheum 1998;41 Suppl:S55.
31. van de Putte LB, van Riel PL, den Broeder A, et al. A single dose placebo controlled phase I study of the fully human anti-TNF antibody D2E7 in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 1998;41 Suppl:S57.
32. Rau R, Simianer S, Weier R, et al. Effective combination of the fully human anti-TNF antibody D2E7 and methotrexate in active rheumatoid arthritis [abstract]. Ann Rheum Dis 1999;Suppl:A907.
33. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
34. van der Heijde DM, van't Hof MA, van Riel PL, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990;49:916-20.
35. van Gestel AM, Prevoo ML, van't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34-40.
36. Kuijpers TW, Tool AT, van der Schoot CE, et al. Membrane surface antigen expression on neutrophils: a reappraisal of the use of surface markers for neutrophil activation. Blood 1991;78:1105-11.
37. van Lent PL, Van den Hoek AE, van den Bersselaar LA, et al. In vivo role of phagocytic synovial lining cells in onset of experimental arthritis. Am J Pathol 1993;143:1226-37.
38. Kessels GC, Krause KH, Verhoeven AJ. Protein kinase C activity is not involved in N-formylmethionyl-leucyl-phenylalanine-induced phospholipase D activation in human neutrophils, but is essential for concomitant NADPH oxidase activation: studies with a staurosporine analogue with improved selectivity for protein kinase C. Biochem J 1993;292:781-5.
39. van Gelder BF, Slater EC. The extinction coefficient of cytochrome c. Biochem Biophys Acta 1962;58:593-5.
40. de Bois MH, Arndt JW, van der Velde EA, et al. 99mTc human immunoglobulin scintigraphy - a reliable method to detect joint activity in rheumatoid arthritis. J Rheumatol 1992;19:1371-6.
41. Liberatore M, Clemente M, Iurilli AP, et al. Scintigraphic evaluation of disease acfivity in rheumatoid arthritis: a comparison of technetium-99m human non-specific immunoglobulins, leucocytes and albumin nanocolloids. Eur J Nucl Med 1992;19:853-7.
42. Jones AK, al Janabi MA, Solanki K, et al. In vivo leukocyte migration in arthritis. Arthritis Rheum 1991;34:270-5.
43. Taylor PC, Peters AM, Paleolog E, et al. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum 2000;43:38-47.
44. van Leeuwen MA, Westra J, Limburg PC, van Riel PL, van Rijswijk MH. Interleukin-6 in relation to other proinflammatory cytokines, chemotactic activity and neutrophil activation in rheumatoid synovial fluid. Ann Rheum Dis 1995;54:33-8.
45. Miesel R, Murphy MP, Kroger H. Enhanced mitochondrial radical production in patients with rheumatoid arthritis correlates with elevated levels of tumor necrosis factor alpha in plasma. Free Radic Res 1996;25:161-9.
46. Kempeni J. Preliminary results of early clinical trials with the fully human anti-TNF alpha monoclonal antibody D2E7. Ann Rheum Dis 1999;58 Suppl 1:170-2.
47. Kettritz R, Falk RJ, Jennette JC, Gaido ML. Neutrophil superoxide release is required for spontaneous and FMLP-mediated but not for TNF alpha-mediated apoptosis. J Am Soc Nephrol 1997; 8:1091-100.